Latest Intravascular ultrasound Stories
Prospective, Multi-Center, Double-Blinded Study Confirms Prior Results in evaluating Volcano's iFR® (Instant Wave-Free Ratio(TM)) Software Modality in a Large, Real-World Population SAN DIEGO and PARIS, May 23, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced preliminary results from the ADVISE...
IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX CALGARY, April 18, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low HDL and ApoA-I (n=324). These target...
Results from REMEDEE Confirm that the COMBO Stent Is Non-Inferior to DES HONG KONG, April 16, 2013 /PRNewswire/ -- OrbusNeich today announced that data from the REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) study published online in JACC: Cardiovascular Interventions demonstrated that the COMBO Dual Therapy Stent met the study's primary endpoint and was found to be effective in controlling neointimal proliferation. Specifically, the COMBO Stent...
-- Three-year clinical results for treating clogged vessels in the heart with Absorb presented at American College of Cardiology 2013 SAN FRANCISCO, March 11, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced positive long-term results for the company's innovative Absorb(TM) Bioresorbable Vascular Scaffold (BVS). Three-year results from 101 patients in the second stage of the ABSORB trial were presented at the 62nd Annual Scientific Session of the American College of...
ALBANY, New York, February 19, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Interventional Cardiology Devices Market (Bare Metal/Drug Eluting/Bio-absorbable Stents, PTCA Balloons, Scoring Balloons, Guidewires, Guiding Catheters, Angiography Catheters, IVUS, Balloon Inflation Devices) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018," the global market for...
TORONTO, Feb. 7, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, interventional cardiologists looking for ways to improve outcomes and avoid unnecessary revascularization procedures are looking carefully at the available clinical evidence supporting the use of intravascular and assessment devices. These physicians see the value in fractional flow reserve (FFR) pressure guidewires, but are more...
SAN DIEGO, Feb. 1, 2013 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it has a new interactive educational tool to facilitate learning about IVUS-guided interventional procedures with its new Visions(®) PV .035 Digital IVUS Catheter. The new Aortic IVUS App for iPad, available on the Apple App Store,...
TORONTO, Jan. 31, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European interventional cardiology market will barely grow through 2017. Procedure growth will average around one percent per year, while revenue growth will be less than that. The market will be just over $1 billion by 2017. There will be a few bright spots of growth, including bioresorbable stents and intravascular imaging....
TORONTO, Jan. 8, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, declines in procedure volumes in the United States interventional cardiology (IC) market will lead to a long-term contraction. As a result of the procedure volume decline, coupled with increasing cost sensitivity, this market will show a steady contraction from a value of just under $2.5 billion in 2012 to just under $2 billion by 2017....
SAN DIEGO, Nov. 23, 2012 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it has entered into a definitive agreement to acquire Sync-Rx Ltd., a privately-held company based in Israel that develops advanced software applications that optimize and facilitate transcatheter cardiovascular...
